This Article Free upon publication Full Text Full Text (PDF) Correction (v113,pe695) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stenestrand, U. Search for Related Content PubMed PubMed Citation Articles by Stenestrand, U. Related Collections Coumarins Acute myocardial infarction Arrhythmias, clinical electrophysiology, drugs Related Article

(Circulation. 2005;112:3225-3231.)
© 2005 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome

A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)

Ulf Stenestrand, MD, PhD; Johan Lindbäck, MSc; Lars Wallentin, MD, PhD, for the RIKS-HIA Registry

From the Department of Cardiology (U.S.), University Hospital of Linköping, Sweden, and Uppsala Clinical Research Center (J.L., L.W.), University Hospital Uppsala, Sweden.

Correspondence to Ulf Stenestrand, MD, PhD, Department of Cardiology, University Hospital, SE 581 85 Linköping, Sweden. E-mail stenestrand{at}riks-hia.se

Received March 30, 2005; revision received July 8, 2005; accepted July 25, 2005.

Background— The American and European guidelines do not agree with regard to antithrombotic treatment in patients with atrial fibrillation (AF) and acute myocardial infarction (AMI), thus causing uncertainty among physicians. We investigated the prescription of oral anticoagulation (OAC) in patients discharged alive with AF after an AMI and the influence of OAC treatment on 1-year mortality.

Methods and Results— This was a prospective cohort study using data from the Register of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) on patients admitted to the coronary care units of 72 Swedish hospitals from 1995 to 2002. A total of 6182 patients discharged alive with first registry-recorded AMI and AF on discharge ECG were included. One-year mortality data were obtained from the Swedish National Cause of Death Register. Only 30% (n=1848) of the 6182 patients with AF were prescribed OAC. At 1 year, the unadjusted mortality was 31% (1183 deaths) in the platelet-inhibitors only group and 22% (414 deaths) in the OAC-treated group. In Cox regression analysis with adjustment for confounding factors, OAC treatment was associated with a reduction in 1-year mortality (relative risk 0.73; 95% CI 0.62 to 0.86; P<0.001) in hospital survivors of AMI with AF. The reduction in mortality appeared to be caused primarily by a lower rate of ischemic heart death (55.6% versus 62.0%) and fatal stroke (5.7% versus 7.5%) in the OAC group. This reduction of mortality was similar among most subgroups based on age, sex, baseline characteristics, previous disease manifestations, and medications.

Conclusions— In daily clinical practice, OAC was only given to a minority (30%) of AMI patients with AF, despite the fact that OAC was associated with a 29% relative and 7% absolute reduction in 1-year mortality after adjustment for confounding variables. The results emphasize the importance of OAC treatment for AF after AMI.

Key Words: anticoagulants • complications • myocardial infarction • patients • prognosis • atrial fibrillation

Related Article:

Issue Highlights
Circulation 2005 112: 3211. [Full Text]

This article has been cited by other articles:

				L. Baruch, B. F. Gage, J. Horrow, S. Juul-Moller, A. Labovitz, M. Persson, and M. Zabalgoitia Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified? Stroke, September 1, 2007; 38(9): 2459 - 2463. [Abstract] [Full Text] [PDF]

				J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]

				C.-W. Siu, M.-H. Jim, H.-H. Ho, R. Miu, S. W.L. Lee, C.-P. Lau, and H.-F. Tse Transient Atrial Fibrillation Complicating Acute Inferior Myocardial Infarction: Implications for Future Risk of Ischemic Stroke Chest, July 1, 2007; 132(1): 44 - 49. [Abstract] [Full Text] [PDF]

				U. Stenestrand, J. Lindback, L. Wallentin, and for the RIKS-HIA Registry Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA, October 11, 2006; 296(14): 1749 - 1756. [Abstract] [Full Text] [PDF]

				K. A.A. Fox Registries and surveys in acute coronary syndrome Eur. Heart J., October 1, 2006; 27(19): 2260 - 2262. [Full Text] [PDF]

				F. G. Kushner and E. M. Antman Oral Anticoagulation for Atrial Fibrillation After ST-Elevation Myocardial Infarction: New Evidence to Guide Clinical Practice Circulation, November 22, 2005; 112(21): 3212 - 3214. [Full Text] [PDF]